GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DARA Biosciences Inc (NAS:DARA) » Definitions » Cyclically Adjusted FCF per Share

DARA Biosciences (DARA Biosciences) Cyclically Adjusted FCF per Share : $0.00 (As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is DARA Biosciences Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

DARA Biosciences's adjusted free cash flow per share for the three months ended in Sep. 2015 was $-0.116. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Sep. 2015.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-05), DARA Biosciences's current stock price is $0.88. DARA Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2015 was $0.00. DARA Biosciences's Cyclically Adjusted Price-to-FCF of today is .


DARA Biosciences Cyclically Adjusted FCF per Share Historical Data

The historical data trend for DARA Biosciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DARA Biosciences Cyclically Adjusted FCF per Share Chart

DARA Biosciences Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DARA Biosciences Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DARA Biosciences's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, DARA Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DARA Biosciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DARA Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where DARA Biosciences's Cyclically Adjusted Price-to-FCF falls into.



DARA Biosciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, DARA Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2015 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2015 (Change)*Current CPI (Sep. 2015)
=-0.116/100.3915*100.3915
=-0.116

Current CPI (Sep. 2015) = 100.3915.

DARA Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200512 -844.375 83.032 -1,020.908
200603 -665.100 84.298 -792.077
200606 -864.900 85.606 -1,014.285
200609 -704.400 85.606 -826.064
200612 -603.900 85.142 -712.066
200703 -2.447 86.640 -2.835
200706 -809.333 87.906 -924.286
200709 44.665 87.964 50.975
200712 -18.187 88.616 -20.604
200803 -6.289 90.090 -7.008
200806 -8.029 92.320 -8.731
200809 -9.241 92.307 -10.050
200812 -3.859 88.697 -4.368
200903 -3.293 89.744 -3.684
200906 -2.147 91.003 -2.368
200909 -1.888 91.120 -2.080
200912 -2.772 91.111 -3.054
201003 -1.941 91.821 -2.122
201006 -2.254 91.962 -2.461
201009 -2.374 92.162 -2.586
201012 -1.633 92.474 -1.773
201103 -1.615 94.283 -1.720
201106 -1.153 95.235 -1.215
201109 -1.191 95.727 -1.249
201112 -0.823 95.213 -0.868
201203 -0.935 96.783 -0.970
201206 -1.089 96.819 -1.129
201209 -0.538 97.633 -0.553
201212 -0.650 96.871 -0.674
201303 -0.652 98.209 -0.666
201306 -0.460 98.518 -0.469
201309 -0.448 98.790 -0.455
201312 -0.271 98.326 -0.277
201403 -0.286 99.695 -0.288
201406 -0.203 100.560 -0.203
201409 -0.093 100.428 -0.093
201412 -0.098 99.070 -0.099
201503 -0.109 99.621 -0.110
201506 -0.141 100.684 -0.141
201509 -0.116 100.392 -0.116

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


DARA Biosciences  (NAS:DARA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


DARA Biosciences Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of DARA Biosciences's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


DARA Biosciences (DARA Biosciences) Business Description

Industry
Traded in Other Exchanges
N/A
Address
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
Executives
David Drutz director, officer: Executive Chairman and CMO 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David L. Tousley officer: CFO 14610 PAWNEE LANE, LEAWOOD KS 66224
Gail Lieberman director 175 EAST 79TH STREET, APT. 4D, NEW YORK NY 10075
Paul John Richardson director 17 COUNTRY OAKS ROAD, LEBANON NJ 08833
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Ann A Rosar officer: Vice President Finance C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Geert Cauwenbergh director 1 STULTS DRIVE, PLAINSBORO NJ 08536
Kurt M Eichler director C/O SPRING BANK PHARMACEUTICALS, INC., STE S-7, MILFORD MA 01757
Hamilton Jordan director
Stuart C Mcwhorter director 113 SEABOARD LANE, FRANKLIN TN 37067
Timothy J Barberich director 40 ELM ST, CONCORD MA 01752
Michael P Duffy officer: SVP, GC and Secretary C/O POINT THERAPEUTICS INC, 125 SUMMER STREET SUITE 1840, BOSTON MA 02110
Richard J Benjamin director 15 WHITE PINE ROAD, NEWTON MA 02464
Larry G Pickering director 26130 MANDEVILLA DRIVE, BONITA SPRINGS FL 34134

DARA Biosciences (DARA Biosciences) Headlines